IL252866B - History of imidazopyridazine as pi3k beta inhibitors - Google Patents
History of imidazopyridazine as pi3k beta inhibitorsInfo
- Publication number
- IL252866B IL252866B IL252866A IL25286617A IL252866B IL 252866 B IL252866 B IL 252866B IL 252866 A IL252866 A IL 252866A IL 25286617 A IL25286617 A IL 25286617A IL 252866 B IL252866 B IL 252866B
- Authority
- IL
- Israel
- Prior art keywords
- pi3kbeta
- inhibitors
- imidazopyridazine derivatives
- imidazopyridazine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Taps Or Cocks (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199322 | 2014-12-19 | ||
| PCT/EP2015/080604 WO2016097347A1 (en) | 2014-12-19 | 2015-12-18 | IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL252866A0 IL252866A0 (en) | 2017-08-31 |
| IL252866B true IL252866B (en) | 2020-09-30 |
Family
ID=52134002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL252866A IL252866B (en) | 2014-12-19 | 2017-06-13 | History of imidazopyridazine as pi3k beta inhibitors |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10087187B2 (enExample) |
| EP (1) | EP3233862B1 (enExample) |
| JP (1) | JP6568588B2 (enExample) |
| KR (1) | KR20170095239A (enExample) |
| CN (1) | CN107108634B (enExample) |
| AU (1) | AU2015366190B2 (enExample) |
| BR (1) | BR112017012930A2 (enExample) |
| CA (1) | CA2967551A1 (enExample) |
| CY (1) | CY1122381T1 (enExample) |
| DK (1) | DK3233862T3 (enExample) |
| EA (1) | EA029789B1 (enExample) |
| ES (1) | ES2761051T3 (enExample) |
| HR (1) | HRP20191550T1 (enExample) |
| HU (1) | HUE045220T2 (enExample) |
| IL (1) | IL252866B (enExample) |
| LT (1) | LT3233862T (enExample) |
| MA (1) | MA41174B1 (enExample) |
| MD (1) | MD3233862T2 (enExample) |
| ME (1) | ME03517B (enExample) |
| MX (1) | MX2017008074A (enExample) |
| PL (1) | PL3233862T3 (enExample) |
| PT (1) | PT3233862T (enExample) |
| RS (1) | RS59301B1 (enExample) |
| SI (1) | SI3233862T1 (enExample) |
| SM (1) | SMT201900509T1 (enExample) |
| WO (1) | WO2016097347A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2905673T3 (es) | 2015-10-09 | 2022-04-11 | Janssen Pharmaceutica Nv | Derivados de quinoxalina y piridopirazina como inhibidores de PI3KBETA |
| KR102472453B1 (ko) | 2016-06-16 | 2022-11-29 | 얀센 파마슈티카 엔.브이. | Pi3k 베타 저해제로서의 이환식 피리딘, 피라진, 및 피리미딘 유도체 |
| CA3054107A1 (en) | 2017-03-29 | 2018-10-04 | Janssen Pharmaceutica Nv | Quinoxaline and pyridopyrazine derivatives as pi3k-beta inhibitors |
| US12281119B2 (en) * | 2019-02-07 | 2025-04-22 | Beigene, Ltd. | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist |
| CN110128505A (zh) * | 2019-05-21 | 2019-08-16 | 梯尔希（南京）药物研发有限公司 | 一种戈舍瑞林杂质的合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| EP2046333A4 (en) | 2006-07-24 | 2010-09-15 | Glaxosmithkline Llc | THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE |
| EP2063962A2 (en) | 2006-09-07 | 2009-06-03 | Biogen Idec MA Inc. | Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
| EP2155753A1 (en) * | 2007-05-09 | 2010-02-24 | Novartis Ag | Substituted imidazopyridazines as pi3k lipid kinase inhibitors |
| EP2217601A1 (en) | 2007-11-08 | 2010-08-18 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyridazines for use as protein kinase inhibitors |
| JP5576802B2 (ja) * | 2008-02-28 | 2014-08-20 | ノバルティス アーゲー | Ｃ−Ｍｅｔチロシンキナーゼ介在疾患の治療用のイミダゾ［１，２−ｂ］ピリダジン誘導体 |
| WO2010007099A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Limited | 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
| JP5819831B2 (ja) | 2009-08-17 | 2015-11-24 | インテリカイン， エルエルシー | 複素環式化合物およびそれらの使用 |
| DE102009049679A1 (de) * | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
| WO2011058109A1 (en) | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors |
| UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| ES2616238T3 (es) | 2010-10-06 | 2017-06-12 | Glaxosmithkline Llc, Corporation Service Company | Derivados de bencimidazol como inhibidores de PI3 quinasa |
| US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
| US9096605B2 (en) * | 2011-08-24 | 2015-08-04 | Glaxosmithkline Llc | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors |
| WO2013095761A1 (en) | 2011-12-20 | 2013-06-27 | Glaxosmithkline Llc | Imidazopyridine derivatives as pi3 kinase inhibitors |
| US8778937B2 (en) | 2011-12-20 | 2014-07-15 | Glaxosmithkline Llc | Benzimidazole boronic acid derivatives as PI3 kinase inhibitors |
| TWI574962B (zh) * | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途 |
| GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
-
2015
- 2015-12-18 JP JP2017532819A patent/JP6568588B2/ja not_active Expired - Fee Related
- 2015-12-18 AU AU2015366190A patent/AU2015366190B2/en not_active Ceased
- 2015-12-18 ES ES15810784T patent/ES2761051T3/es active Active
- 2015-12-18 ME MEP-2019-263A patent/ME03517B/me unknown
- 2015-12-18 BR BR112017012930A patent/BR112017012930A2/pt active Search and Examination
- 2015-12-18 HR HRP20191550 patent/HRP20191550T1/hr unknown
- 2015-12-18 RS RSP20191225 patent/RS59301B1/sr unknown
- 2015-12-18 LT LTEP15810784.7T patent/LT3233862T/lt unknown
- 2015-12-18 US US15/537,551 patent/US10087187B2/en active Active
- 2015-12-18 EP EP15810784.7A patent/EP3233862B1/en active Active
- 2015-12-18 EA EA201791396A patent/EA029789B1/ru not_active IP Right Cessation
- 2015-12-18 HU HUE15810784A patent/HUE045220T2/hu unknown
- 2015-12-18 WO PCT/EP2015/080604 patent/WO2016097347A1/en not_active Ceased
- 2015-12-18 MX MX2017008074A patent/MX2017008074A/es active IP Right Grant
- 2015-12-18 SM SM20190509T patent/SMT201900509T1/it unknown
- 2015-12-18 CN CN201580069133.7A patent/CN107108634B/zh not_active Expired - Fee Related
- 2015-12-18 MA MA41174A patent/MA41174B1/fr unknown
- 2015-12-18 PL PL15810784T patent/PL3233862T3/pl unknown
- 2015-12-18 MD MDE20170191 patent/MD3233862T2/ro not_active IP Right Cessation
- 2015-12-18 KR KR1020177016722A patent/KR20170095239A/ko not_active Ceased
- 2015-12-18 CA CA2967551A patent/CA2967551A1/en active Pending
- 2015-12-18 SI SI201530855T patent/SI3233862T1/sl unknown
- 2015-12-18 PT PT158107847T patent/PT3233862T/pt unknown
- 2015-12-18 DK DK15810784.7T patent/DK3233862T3/da active
-
2017
- 2017-06-13 IL IL252866A patent/IL252866B/en active IP Right Grant
-
2019
- 2019-10-03 CY CY20191101031T patent/CY1122381T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA41174A (fr) | 2017-10-25 |
| PL3233862T3 (pl) | 2020-01-31 |
| PT3233862T (pt) | 2019-10-09 |
| WO2016097347A1 (en) | 2016-06-23 |
| RS59301B1 (sr) | 2019-10-31 |
| SMT201900509T1 (it) | 2019-11-13 |
| CN107108634B (zh) | 2020-09-15 |
| EP3233862B1 (en) | 2019-07-03 |
| EP3233862A1 (en) | 2017-10-25 |
| AU2015366190A1 (en) | 2017-05-25 |
| CN107108634A (zh) | 2017-08-29 |
| US20180002336A1 (en) | 2018-01-04 |
| CA2967551A1 (en) | 2016-06-23 |
| HUE045220T2 (hu) | 2019-12-30 |
| KR20170095239A (ko) | 2017-08-22 |
| BR112017012930A2 (pt) | 2018-01-09 |
| DK3233862T3 (da) | 2019-10-07 |
| HRP20191550T1 (hr) | 2019-11-29 |
| JP6568588B2 (ja) | 2019-08-28 |
| CY1122381T1 (el) | 2021-01-27 |
| ES2761051T3 (es) | 2020-05-18 |
| IL252866A0 (en) | 2017-08-31 |
| MX2017008074A (es) | 2018-01-09 |
| LT3233862T (lt) | 2019-09-10 |
| US10087187B2 (en) | 2018-10-02 |
| SI3233862T1 (sl) | 2019-09-30 |
| EA029789B1 (ru) | 2018-05-31 |
| JP2017538734A (ja) | 2017-12-28 |
| MA41174B1 (fr) | 2019-09-30 |
| ME03517B (me) | 2020-04-20 |
| EA201791396A1 (ru) | 2017-10-31 |
| AU2015366190B2 (en) | 2020-01-23 |
| MD3233862T2 (ro) | 2019-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | smyd inhibitors | |
| IL246785A0 (en) | Benzimidazole-2-amines as midh1 inhibitors | |
| IL251420A0 (en) | Triazolopyrazinones as pde1 inhibitors | |
| SG11201610904UA (en) | Syk inhibitors | |
| IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| IL251932B (en) | Benzylpropargyl ether as nitrification inhibitors | |
| IL251778B (en) | Novel pyrazolopyrimidine histories as nik inhibitors | |
| SG11201609205WA (en) | Heterocyclyl-butanamide derivatives | |
| PL3164393T3 (pl) | Pochodne flawaglin | |
| HUE050450T2 (hu) | Fluoralkil-fluorén-származékok | |
| IL248773A0 (en) | History of naphthyridinedione | |
| IL252866B (en) | History of imidazopyridazine as pi3k beta inhibitors | |
| IL248629A0 (en) | Substances containing diheteroaryl conjugated to cycloalkyl and their uses | |
| IL246718A0 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
| PL3119744T3 (pl) | Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu | |
| IL252868A0 (en) | History of heterocyclyl-related imidazopyridazines as pi3kbeta inhibitors | |
| GB201418154D0 (en) | Inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |